Psychiatry · OCDTrial Updateclinicalmid-term

Study on Imagery Rescripting vs Exposure for OCD by King's College London

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 12:30:59 PM

Assessment confidence: 55% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial comparing imagery rescripting and exposure therapy for OCD could reshape treatment paradigms in psychiatry. Outcomes may influence product development and market positioning for existing therapies targeting OCD. Regulatory context from MHRA (Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

Strategic Assessment

The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In Psychiatry · OCD, 6 regulatory and 2 competitive items passed relevance filtering for pharmaceutical companies developing OCD treatments. Depending on the trial results, there could be shifts in market share among existing OCD treatments, impacting revenue for companies involved in this therapeutic area.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT. This research could influence treatment approaches for OCD, potentially impacting existing therapies and their market positions.

Regulatory Outlook

Regulatory risk is concentrated around Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, PMDA, FDA. The trial's findings are unlikely to directly affect regulatory approvals but may inform future clinical guidelines and treatment recommendations.

Key Opportunities

Depending on the trial results, there could be shifts in market share among existing OCD treatments, impacting revenue for companies involved in this therapeutic area.
The outcomes of this trial for future OCD treatment strategies and potential product development.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and publication of findings to assess the impact on OCD treatment paradigms.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
[PMDA]PMDA Concludes Memorandum of Understanding with the London School of Hygiene & Tropical Medicine (LSHTM) (News Release) (July 6, 2026) [222KB]
PMDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Support and Strengthen Domestic Drug Manufacturing
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots webpage
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Study Data Technical Conformance Guide - Technical Specifications Document
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Neurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Association Between the Stress Hormone Cortisol and Decision-making
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
Humanexa Signalsmedium relevance
Moderate corpus alignment

Peer-delivered combined EMD and imagery rescripting for traumatized Chinese university students: RCT.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Association of Intraoperative Fluid Exposure with Time to First Flatus after Laparoscopic Radical Resection for Colorectal Cancer: A Retrospective Cohort Study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

pharmaceutical companies developing OCD treatments

Commercial impact

medium

Depending on the trial results, there could be shifts in market share among existing OCD treatments, impacting revenue for companies involved in this therapeutic area.

Regulatory impact

low

The trial's findings are unlikely to directly affect regulatory approvals but may inform future clinical guidelines and treatment recommendations.

What to watch

Monitor trial results and publication of findings to assess the impact on OCD treatment paradigms.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.